18F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究*

doi:10.3969/j.issn.1672-5069.2019.02.025

摘要/Abstract

摘要： 目的研究¹⁸氟-代脱氧葡萄糖电子发射断层显像术/x线计算机体层摄影术（18F-FDG PET/CT）检查预测肝细胞癌（HCC）微血管侵犯（MVI）患者的临床意义。方法 2014年2月~2015年12月我院诊治的HCC患者99例,接受¹⁸F-FDG PET/CT检查,然后行肝叶切除术。结果在99例HCC患者中,经术后组织病理学检查,证实有MVI患者42例,无MVI患者57例;¹⁸F-FDG PET/CT检查结果显示,肝内肿瘤表现为低密度或稍低密度阴影,病灶呈不规则状,大多数情况呈类圆形,部分肿瘤周围伴有子灶。PET/CT检查显像阳性73例（73.7%）,其中MVI阳性组为85.7%,显著高于MVI阴性组的64.9%（P<0.05）; MVI阳性组肿瘤直径为（7.6±2.8） cm,显著大于MVI阴性组的（5.4±2.4） cm,肿瘤最大标准摄取值（SUVmax）为（7.4±5.2）,显著高于MVI阴性组的【（5.3±5.2）,P<0.05】;MVI阳性与MVI阴性患者肿瘤组织学类型差异无统计学意义（P>0.05）,但MVI阳性患者肿瘤分化为III/IV型比例显著高于MVI阴性患者（88.1%对75.4%,P<0.05）;术后随访12~24个月,中位随访时间为18个月,99例HCC患者1 a总体生存率为81.8%,无瘤生存率为60.6%,其中MVI阳性组1 a总体生存率和无瘤生存率分别为66.7%和47.6%,显著低于MVI阴性组的91.2%和70.2%（P<0.05）。结论肝细胞癌伴有微血管侵犯患者在行18F-FDG PET/CT检查时有一些特点值得总结和观察,其临床意义还需要进一步探讨。

关键词: 肝细胞癌, ¹⁸F-FDG PET/CT, 微血管侵犯, 生存率

Abstract: Objective To explore the clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma （HCC） and hepatic microvascular invasion （MVI）. Methods We retrospectively analyzed the clinical materials of 99 patients with HCC who admitted to our hospital between February 2014 and December 2015. All these 99 patients received ¹⁸F-FDG PET/CT scan and hepatectomy thereafter,and the postoperative histopathological examination was done to confirm the existence of MVI. Results Out of the 99 patients with HCC,the postoperative pathological examination showed the existence of MVI in 42,and without MVI in 57 cases;the ¹⁸F-FDG PET/CT scan showed that the intrahepatic tumor irregular and mostly rounded,some accompanied by subfoci,presenting with low density or slightly low density shadows. The PET/CT examination was positive in 73（73.7%） cases,85.7% in patients with MVI,and 64.9% in patients without MVI（P<0.05）;the tumor diameter in patients with MVI positive was （7.6±2.8） cm,significantly larger than（5.4±2.4） cm in patients without MVI,and the tumor maximum standardized uptake value （SUVmax） was （7.4±5.2）,significantly higher than 【（5.3±5.2）,P<0.05】 in patients with MVI negative;the histological types of hepatocellular carcinoma in patients with and without MVI were not significantly different （P>0.05）,while the percentage of tumor differentiation type III/IV was much higher in patients with MVI as compared to that in patients without （88.1% vs. 75.4%,P<0.05）;all the patients were followed-up for 12 to 24 months with the median of 18 months,the one-year total survival was 81.8% and the disease-free survival rate was 60.6%;further analysis showed that the one-year survival and one-year disease-free survival rate in patients with MVI positive were 66.7% and 47.6%,significantly lower than 91.2% and 70.2%,respectively （P<0.05） in patients with MVI negative. Conclusion s The patients with hepatocellular carcinoma and hepatic microvascular invasion have some characteristics when the ¹⁸F-FDG PET/CT scan is done,which should be summarized and its implications needs further investigation.

Key words: Hepatocellular carcinoma, ¹⁸F-FDG PET/CT scan, Microvascular invasion, Survival

幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.

Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.

参考文献

[1] Castilla-Lievre MA,Franco D,Gervais P,et al.Diagnostic value of combining 11 C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging,2016,43(5):852-859.
[2] 刘东锋旋,张峰旋,潘贤成旋,等. ¹⁸F-FDG PET/CT双时相显像在肝癌诊断中的应用价值探讨.实用肝脏病杂志,2016,19(4):463-466.
[3] Lee E,Park CM,Kang KW,et al.¹⁸F-FDG PET/CT features of pulmonary sclerosing hemangioma. Acta Radiol,2013,54(1):24-29.
[4] Ishizaki Y,Kawasaki S.The evolution of liver transplantation for hepatocellular carcinoma (past,present,and future). J Gastroenterol,2008,43:18-26.
[5] 李洪生,吴湖炳,王全师,等. 18F -FDG PET/CT在肝癌治疗后AFP升高患者中的应用. 中华核医学与分子影像杂志,2008,28(5):310-312.
[6] Mazzaferro V,Regalia E,Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med,1996,334:693-699.
[7] Torte LA,Bray F,Siegel RL,el a1.Global cancer statistics,2012.CA Cancer J Clin,2015,65(2):87-108.
[8] Kishida Y,Seki S,Yoshikawa T,et al.Performance comparison between ¹⁸F-FDG PET/CT plus brain MRI and conventional staging plus brain MRI in staging of small cell lung carcinoma. Am J Roentgenol,2018,211(1):185-192.
[9] Kirimlioglu H,Dvorchick I,Ruppert K,et al.Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation:Biologic and therapeutic implications. Hepatology,2001,34:502-510.
[10] 白璐,尚进,刘翔,等. ¹⁸F-FDG PET/CT显像对原发性肝癌分化程度和临床分期的评估价值. 实用放射学杂志,2015,31(12):424-417.
[11] Teefey SA,Hildeboldt CC,Dehdashti F,et al.Detection of primary hepatic malignancy in liver transplant candidates:Prospective comparison of CT,MR imaging,US,and PET. Radiology,2003,226:533-542.
[12] 滕学鹏,孙晓蓉,穆殿斌,等. 胃肝样腺癌¹⁸F-FDG PET/CT检查1例. 中华核医学与分子影像杂志,2012,32(4):304-305.
[13] Zavaglia C,De Carlis L,Alberti AB,et al.Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol,2005,100:2708-2716.
[14] Lin CY,Chen JH,Liang JA,et al.¹⁸F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma:a systematic review and meta-analysis. Eur J Radiol,2012,81(9):2417-2422.
[15] 王艳丽,房娜,曾磊,等. ¹⁸F-FDG PET/CT对高¹⁸F-FDG摄取肝细胞肝癌经动脉插管化疗栓塞的疗效评价. 中华核医学与分子影像杂志,2013,33(5):328-331.
[16] Kim SM,Sang SS,Lee BC,et al.Imaging evaluation of ablative margin and index tumor immediately after radiofrequency ablation for hepatocellular carcinoma:comparison between multidetector-row CT and MR imaging. Abdom Radiol (NY),2017,42(10):2527-2537.
[17] 贾佳,祁兴顺,韩国宏. ¹⁸F-FDGPET/CT评价肝癌预后的价值. 中华消化病与影像杂志(电子版),2014,4(3):33-37.
[18] Ma W,Jia J,Wang S,et al.The prognostic value of ¹⁸F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics,2014,4(7):736-744.
[19] 吴冰,韩磊,姜磊,等. ¹⁸F-FDG PET/CT双时相显像在肝细胞肝癌诊断中的应用价值. 中华核医学与分子影像杂志,2014,34(1):58-59.
[20] Wang HY,Jeng LB,Lin MC,et al.¹⁸F-FDG PET/CT in detection of gynecomastia in patients with hepatocellular carcinoma. Clin Imaging,2013,37(5):942-946.
[21] Chan SC,Yeh CH,Yen TC,et al.Clinical utility of simultaneous whole-body ¹⁸F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging,2018,45(8):1297-1308.
[22] Konishi H,Takehara K,Kojima A,et a1.Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma.Int J Gynecol Cancer,2014,24(7):1190-1194.
[23] Su YA,Lee JM,Joo I,et al.Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and ¹⁸F-FDG PET/CT. Abdom Imaging,2014,40(4):843-851.

¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*

Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[7]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[11]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[12]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[13]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.
[14]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.
[15]	许达峰, 周开伦, 李灼日, 武金才, 陈鑫苹, 张震生, 郑进方, 王雨, 刘向梅. miR-144脂质体复合物体外抑制肝癌细胞增殖和侵袭能力及对裸鼠种植肿瘤的抑制作用初步研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 25-28.